Ascendis continued big investments into 2021, driving operating deficit up

Ramped up investing into sales and research helped drive up the operational deficit at biotech firm Ascendis Pharma. Even so, the company’s 2021 growth matched that of recent years.

Photo: Kevin Grønnemann / MedWatch

Danish biotech company Ascendis Pharma, which is listed in the US, continued on its growth track in 2021, booking a revenue of EUR 7.8m compared to preceding year’s EUR 7.8m, the company’s full-year report states.

Ascendis Pharma also increased its operating deficit from EUR 331m to EU 452m in the recently concluded year. The reason for this is investments into the company’s research and development, where expenses grew from EUR 261m to EUR 296m. On top of this, the item ”selling, general and administrative expenses” went up from EUR 77m to EUR 160m.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs